Testing depemokimab for COPD with type 2 inflammation
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests an early treatment called depemokimab for people with moderate to severe COPD who have a type of inflammation linked to high eosinophils. It aims to reduce flare-ups and improve breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe COPD and your blood test shows high eosinophils (a type of white blood cell linked to inflammation)
- You have had at least 1 moderate flare-up in the past year and have other risk factors for future flare-ups
- You are a current or former smoker with at least a 10 pack-year smoking history
- You take combination inhaler therapy (like ICS+LABA or LABA+LAMA or triple therapy) for at least 3 months
- You have a BMI of 16 or higher and no other major lung disease like asthma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new biologic medicine called depemokimab, given as an injection, to see if it reduces flare-ups (exacerbations) in people with COPD who have a specific type of inflammation (high eosinophils). It may help if you have frequent flare-ups despite using your regular inhalers.
This study tests a new biologic medicine, given as an injection, to see if it can reduce flare-ups in adults with COPD who have a certain type of inflammation. It may help people who still have frequent exacerbations despite using their current inhalers.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
This study tests depemokimab, an injectable biologic, to see how it works in the lungs of people with severe asthma. You would get the drug and have special imaging and a bronchoscopy (a tube with a camera placed into your airways to take tiny tissue samples) so doctors can understand how the medicine reduces inflammation.
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
This study tests a new medicine called depemokimab, given as an injection, to see if it can reduce asthma attacks in people with a specific type of asthma (type 2 high). If you have had asthma for several years and have had recent attacks despite using regular inhalers, this trial might be an option for you.
Hear when a new Pulmonary Disease, Chronic Obstructive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.